Reimbursement for COVID-19 Detection Test in Belgium

23

Mar 2020

Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) has issued an agreement document on March 17, 2020, providing principles for billing and funding the Coronavirus (COVID-19) Detection Tests. Previously in Protocol for Hospitals on March 10, 2020, it was outlined that COVID-19 tests performed outside the National Reference Center for Respiratory Pathogens at UZ Leuven have no specific nomenclature codes, and no reimbursement was provided, therefore, was paid by patients. The new agreement clarifies principles for reimbursement, but the invoicing for the tests still on hold.

Tests to detect the COVID-19 coronavirus are centralized at the National Reference Center for Respiratory Pathogens at UZ Leuven (CNR). For a screening test that is carried out in the CNR, the costs are fully reimbursed by the public authorities, and the patient does not pay anything. INAMI has noted that tests are carried out in different hospitals and laboratories outside of CNR procedures, which can be found on the Sciensano website. As there are no specific nomenclature codes for these tests, it was sometimes charged to patients.

INAMI brought together all the parties concerned - clinical biology laboratories (ambulatory, hospitals, Reference centers), mutual societies, and Sciensano, and issued the agreement document on March 17, providing principles on which further reimbursement for the COVID-19 tests will be based. The most important are:

  • The invoicing for the COVID-19 tests remains on hold
  • Health care insurance will provide full reimbursement, with no possibility of extra charge The funding of the reference center will be adjusted according to the activity carried out
  • Reimbursement will be provided for tests that meet the Sciensano case definition or performed due to a clinical need. Patients do not pay user fees for these tests. For the tests that do not meet these conditions, a maximum amount will be fixed. Specific conditions for repeated tests will be established
  • Laboratory (ambulatory, hospitals, referral centers) collect all the necessary information (number of tests, personnel cost, infrastructure) to determine the reimbursement. They are examining whether the available capacity can be optimized
  • Reimbursement will be provided from a date to be determined (start of the corona crisis)

However, no codes and tariffs are available for now. INAMI will keep the public updated

See the full details in French here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more